Movement Disorder News and Research

Latest Movement Disorder News and Research

Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's

Merck Serono announced today the initiation of the SETTLE study. This study will evaluate the efficacy and safety of a dose range of safinamide (50-100 mg once daily) as add-on therapy to a stable dose of levodopa, in mid- to late-stage Parkinson's disease patients with motor fluctuations compared to placebo.

7 May 2009

Shedding some light on Parkinson's treatment

A research team lead by Karl Deisseroth in the bioengineering department at Stanford University has developed a technique to systematically characterize disease circuits in the brain.

16 Apr 2009

Cognitive behavioral therapy helps alleviate nonepileptic seizures

Researchers at Rhode Island Hospital have found that cognitive behavioral therapy (CBT) can reduce the frequency of seizures in patients with psychogenic nonepileptic seizures (PNES), along with improving their overall quality of life.

15 Apr 2009

Deep brain stimulation effective for patients with primary generalized dystonia

A new study from Mount Sinai School of Medicine finds that deep brain stimulation (DBS) is a safe and effective treatment for patients with primary generalized dystonia (PGD).

14 Apr 2009

RNA interference can be used to silence genes selectively - potential for Huntington's disease therapy

Howard Hughes Medical Institute researchers have designed tiny RNA molecules that shut off the gene that causes Huntington's disease without damaging that gene's healthy counterpart, which maintains the health and vitality of neurons.

12 Apr 2009

University of Florida doctors test targets for Parkinson surgery

Doctors may be able to tailor a specialized form of brain surgery to more closely match the needs of Parkinson patients, according to results from the first large-scale effort to compare the two current target areas of deep brain stimulation surgery, or DBS.

15 Mar 2009

FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs

The U.S. Food and Drug Administration announced today that manufacturers of metoclopramide, a drug used to treat gastrointestinal disorders, must add a boxed warning to their drug labels about the risk of its long-term or high-dose use.

1 Mar 2009

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA has announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours.

5 Feb 2009

Pregnancy-related hormonal changes linked to increased risk of restless legs syndrome

A study in the Feb. 1 issue of the journal Sleep shows that the elevation in estradiol levels that occurs during pregnancy is more pronounced in pregnant women with restless legs syndrome (RLS) than in controls.

2 Feb 2009

Early treatment with rasagiline (Azilect) for Parkinson's best

There is hope that the drug rasagiline can do what no other medication for Parkinson's disease now does -- slow the progression of a devastating degenerative brain disease that eventually robs people of their ability to move and function.

27 Jan 2009

Deep brain stimulation helps advanced Parkinson's disease patients

Patients with advanced Parkinson disease (PD) who received deep brain stimulation treatment had more improvement in movement skills and quality of life after six months than patients who received other medical therapy, but also had a higher risk of a serious adverse events, according to a study in the January 7 issue of JAMA.

6 Jan 2009

FDA issues complete response letter to Ipsen for Dysport BLA

Ipsen has announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its Biologics License Application (BLA) for its Botulinum toxin Type A, Dysport.

30 Dec 2008

Paliperidone palmitate shows positive results for treatment of schizophrenia

Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study.

14 Dec 2008

Losing sense of smell may indicate Parkinson's

Many individuals with Parkinson's disease are able to recall losing their sense of smell well before the onset of more commonly recognized symptoms such as tremors, impaired dexterity, speech problems, memory loss and decreased cognitive ability.

12 Dec 2008

Cambridge Labs announces Spanish approval of Tetrabenazine

Cambridge Laboratories Limited has announced that its flagship product Tetrabenazine, (known as NITOMAN in Germany and other key European territories and XENAZINE in the UK, U.S. and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

8 Dec 2008

Prevalence of vitamin D insufficiency in patients with Parkinson's and Alzheimer's disease

A majority of Parkinson's disease patients had insufficient levels of vitamin D in a new study from Emory University School of Medicine.

13 Oct 2008

Anti-reflux surgery - research may lead to changes in treatment recommendations

Researchers at Wake Forest University Baptist Medical Center have found that the reflux and swallowing problems that are common symptoms in patients with Rett syndrome and other neurological impairments, may be caused by a different mechanism than they are in healthy individuals. The finding leaves researchers to wonder if these patients truly benefit from anti-reflux surgery commonly performed in these children.

4 Aug 2008

Japanese encephalitis damages the brain in two ways

Japanese encephalitis (JE), commonly known as brain fever, is one of the prevalent mosquito-borne encephalitis in India and entire South East (SE) Asia.

8 Jul 2008

New guidelines say botulinum toxin effective for many neurological disorders, but not headache

New guidelines developed by the American Academy of Neurology confirm that the drug botulinum toxin is safe and effective for treating a variety of neurological conditions. Surprisingly, the drug may not be effective for chronic headaches, accrding to Allison Brashear, M.D., professor and chairman of the Department of Neurology at Wake Forest University Baptist Medical Center, who helped develop the guidelines.

9 May 2008

Prana Biotechnology has discovered novel drug candidates for use in Parkinson's disease

Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.

6 May 2008

Movement Disorder News and Research

Latest Movement Disorder News and Research

Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's

Shedding some light on Parkinson's treatment

Cognitive behavioral therapy helps alleviate nonepileptic seizures

Deep brain stimulation effective for patients with primary generalized dystonia

RNA interference can be used to silence genes selectively - potential for Huntington's disease therapy

University of Florida doctors test targets for Parkinson surgery

FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Pregnancy-related hormonal changes linked to increased risk of restless legs syndrome

Early treatment with rasagiline (Azilect) for Parkinson's best

Deep brain stimulation helps advanced Parkinson's disease patients

FDA issues complete response letter to Ipsen for Dysport BLA

Paliperidone palmitate shows positive results for treatment of schizophrenia

Losing sense of smell may indicate Parkinson's

Cambridge Labs announces Spanish approval of Tetrabenazine

Prevalence of vitamin D insufficiency in patients with Parkinson's and Alzheimer's disease

Anti-reflux surgery - research may lead to changes in treatment recommendations

Japanese encephalitis damages the brain in two ways

New guidelines say botulinum toxin effective for many neurological disorders, but not headache

Prana Biotechnology has discovered novel drug candidates for use in Parkinson's disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Movement Disorder News and Research

Latest Movement Disorder News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in